Gene Therapy for Eye Diseases: Bringing Back Sight at the Source
Gene therapy has the promise to revolutionize the treatment of retinal diseases by offering a way to correct the underlying genetic causes of vision loss rather than simply managing symptoms. Through the use of adeno-associated virus (AAV) vectors, therapeutic genes can be delivered directly to retinal cells, potentially restoring their function and preserving or even improving vision. This targeted approach is especially promising for inherited retinal disorders, where a single administration may provide long-lasting benefits. With many eye diseases still experiencing an unmet medical need, gene therapy is emerging as a powerful tool in the fight against blindness, bringing hope to patients with previously untreatable conditions.
What are AAVs?
Adeno-associated virus (AAV) vectors are small, non-pathogenic viruses that naturally infect human cells without causing disease. This makes them ideal tools for gene therapy applications since they can efficiently enter target cells and deliver their genetic cargo for sustained therapeutic effect.
What is Gene Therapy?
Simplistically, gene therapy is a medical approach that treats (or prevents) disease by introducing, removing, or altering genetic material within a patient’s cells. Gene therapy is intended to target the root cause of the disease, either non-functional or dysfunctional genes, by delivering functional genes or modifying existing ones to restore normal cellular function.
Figure: General Principle of Gene Therapy. A mutated gene is replaced or repaired with a functional gene using a delivery method, such as an AAV vector.
Why AAV Gene Therapy for Inherited Eye Diseases?
AAV gene therapy offers a unique advantage by addressing the root cause of vision loss by delivering functional therapeutic genes directly to retinal cells, rather than merely managing symptoms of the disease. AAV vectors are well-suited for ocular applications due to their safety profile, ability to provide long-term gene expression, and low risk of triggering immune responses. The eye’s small, enclosed structure allows localized delivery, reducing systemic exposure and enhancing precision. These qualities make AAV-based therapies especially promising for inherited retinal disorders, where a single treatment can potentially restore or preserve vision for years.
Figure: AAV-Mediated Gene Delivery to the Retina
This illustration shows the process of delivering an adeno-associated virus (AAV) vector into the eye via subretinal injection. The therapy targets retinal cells (e.g., photoreceptors and retinal pigment epithelium (RPE) cells) which are critical for vision.
Benefits and Challenges
While gene therapy for retinal diseases offers groundbreaking potential to restore vision by addressing the root genetic cause, it is not without challenges. These treatments often require complex delivery methods, such as subretinal injections, and their long-term safety and durability are still being studied. High development costs, limited accessibility, and the risk of immune reactions or incomplete gene expression also pose hurdles. As research advances, balancing these benefits and risks will be critical to ensuring safe, effective, and widely available therapies.
Some examples of clinical pipeline candidates utilizing gene therapy for the treatment of retinal diseases are shown below (information sourced from the public domain)
| Aspect | Current Therapeutic Approaches | Gene Therapies |
|---|
| Mechanism of Action | Symptom management (e.g., anti-VEGF to reduce neovascularization, corticosteroids for inflammation) | Targets underlying genetic cause by delivering functional genes to retinal cells |
| Delivery Method | Repeated intravitreal injections, implants, or oral/systemic medications | One-time or infrequent administration via subretinal, intravitreal, or suprachoroidal injection using viral vectors (e.g., AAV) |
| Treatment Frequency | Frequent (monthly or bi-monthly injections) | Potentially one-time or long-interval treatment |
| Target Diseases | AMD, diabetic retinopathy, retinal vein occlusion | Inherited retinal diseases like LCA, RP, Stargardt disease |
| Efficacy | Stabilizes or slows progression; limited vision restoration | Potential for vision restoration or significant improvement in early-stage IRDs |
| Limitations | High treatment burden, variable real-world outcomes, does not address root cause | Limited to specific genetic mutations, high cost, long-term safety still under evaluation |
| FDA Approvals | Multiple approved drugs (e.g., ranibizumab, aflibercept) | One approved gene therapy (Luxturna® for RPE65-related LCA); others in clinical trials |
| Patient Suitability | Broad population including acquired retinal diseases | Patients with confirmed genetic mutations and viable retinal cells |
| Challenges | Adherence, cost, side effects from repeated injections | Immune response, vector delivery limitations, manufacturing complexity |
| Future Potential | Improved drug delivery systems (e.g., sustained-release implants) | Expansion to gene-agnostic therapies, CRISPR-based editing, optogenetics, combination with stem cell therapy |
Table: Current Therapies vs. Gene Therapy for Retinal Diseases
Gene Therapy Clinical Trial Landscape for Retinal Diseases
Gene therapy for retinal disorders is advancing rapidly, with multiple clinical trials targeting inherited retinal diseases and age-related conditions. Some examples of clinical pipeline candidates utilizing gene therapy for the treatment of retinal diseases are shown below:
Stargardt Disease
Sponsor: AAVantgarde Bio (https://www.aavantgarde.com/en/)
- Trial Name: CELESTE
- Investigational Product: AAVB-039
- Phase: 1/2
- Mechanism of Action: AAV-based gene therapy to deliver full-length ABCA4 protein to retinal cells to restore normal protein function and slow retinal degeneration.
- Delivery: Subretinal injection
Sponsor: SpliceBio (https://splice.bio/)
- Trial Name: ASTRA
- Investigational Product: SB-007
- Phase: 1/2
- Mechanism of Action: Dual-AAV gene therapy coupled with a protein splicing platform to restore expression of full-length ABCA4 protein in the retina and restore photoreceptor function.
- Delivery: Subretinal injection
Sponsor: Ocugen Inc. (https://ocugen.com/)
- Trial Name: GARDian3
- Investigational Product: OCU410ST
- Phase: 2/3
- Mechanism of Action: AAV-based gene therapy to deliver the hRORA gene to retinal cells to maintain cellular health and function in the retina and prevent further damage.
- Delivery: Subretinal injection
Retinitis Pigmentosa (RP)
Sponsor: SparingVision (https://sparingvision.com/)
- Trial Name: NYRVANA
- Investigational Product: SPVN20
- Phase: 1 (First-in-Human)
- Mechanism of Action: Gene-agnostic AAV-based gene therapy for the delivery of GIRK to counteract cone dormancy and preserve vision.
- Delivery: Intravitreal injection
Sponsor: Beacon Therapeutics (https://beacontx.com/)
- Trial Name: Landscape
- Investigational Product: Laruparetigene zovaparvovec
- Phase: 2
- Mechanism of Action: AAV-based gene therapy to deliver a full length RPGT gene to address the full complement of photoreceptor damage caused by X-linked RP, including both rod and cone loss.
- Delivery: Subretinal injection
Leber Congenital Amaurosis (LCA)
Sponsor: Opus Genetics (https://opusgtx.com/)
- Trial Name: OPGx-LCA5-1001
- Investigational Product: OPGx-001
- Phase: 1/2
- Mechanism of Action: AAV-based gene therapy to deliver a functional LCA5 gene to photoreceptors in the retina to restore visual function.
- Delivery: Subretinal injection
Sponsor: Atsena Therapeutics (https://atsenatx.com/)
- Trial Name: ATSN-101-1
- Investigational Product: ATSN-101
- Phase: 1/2
- Mechanism of Action: AAV-based gene therapy to deliver a functional GUCY2D gene to photoreceptors in the retina to restore visual function.
- Delivery: Subretinal injection
Age-Related Macular Degeneration (AMD)
Sponsor: Regenxbio / AbbVie (https://www.regenxbio.com/) (https://www.abbvie.com/)
- Trial Name: ASCENT
- Investigational Product: ABBV-RGX-314
- Phase: 3
- Mechanism of Action: AAV-based gene therapy to deliver an antibody fragment to inhibit VEGF, reducing abnormal blood vessel growth and help maintain vision.
- Delivery: Subretinal or suprachoroidal injection
Sponsor: Adverum Biotechnologies (https://www.adverum.com/)
- Trial Name: ARTEMIS
- Investigational Product: Ixoberogene soroparvovec
- Phase: 3
- Mechanism of Action: AAV-based gene therapy to deliver an aflibercept coding sequence to inhibit VEGF, reducing abnormal blood vessel growth and help maintain vision.
- Delivery: Intravitreal injection
Regulatory Oversight and Ethical Review
Gene therapy trials for retinal diseases operate under rigorous regulatory frameworks to ensure patient safety and scientific integrity. Institutional Review Boards (IRBs) play a critical role in evaluating study protocols for ethical compliance, informed consent, and risk-benefit balance. In parallel, Institutional Biosafety Committees (IBCs) assess the safe handling of viral vectors and adherence to biosafety standards, particularly for AAV-based interventions.
Sabai's Role
At Sabai, we work with Sponsors and CROs advancing gene therapies, including those for eye diseases, to guide them through the complex regulatory landscape making sure every study meets the highest ethical and biosafety standards.
Connect with our IRB & IBC experts to ensure your study stays firmly grounded in compliance and compassion.